 |
| Michael Murphy, Chief Executive of NCB Ventures with Vivienne Williams, Managing Director, Cellix |
Cellix Ltd, an instrumentation
company, is providing new
microfluidic technology based
solution in the areas of drug discovery,
diagnostics and medical research.
Cellix is committed to becoming the
leading provider of microfluidic tools
and accessories for the investigation of
new therapies for anti-inflammatory
conditions. The new company was
formed as a spin-out from research
completed in Trinity College Dublin.
Cellix has developed and produced
disposable biochips capable of
mimicking human capillaries.
The company’s products combine
advanced research in the areas of
microfluidics and nanotechnology.
Cellix Limited recently announced
the completion of an €800,000
investment round in the company.
NCB Ventures, the venture
capital arm of NCB Group, led the
investment. Co-investors were OTC,
a French Venture Capital fund and
Enterprise Ireland. The seed capital
raised will be used to finance
the company’s continued R&D
and expansion into international
markets.
The main application of
Cellix products is for cell-based
assays and is ideally suited for
studying cell adhesion, migration,
invasion, chemotaxis and shear
stress models in diseases and
microenvironments.
|
